Related Experiment Videos
Beneficial effects of prostaglandin E1 on myocardial energetics and pump performance in severe CHF
Insights
Prostaglandin E1 (PGE1) effectively treats severe left ventricular failure by acting as an arteriolar vasodilator. This improves cardiac function and myocardial energetics in patients with ischemic congestive heart failure.
Area of Science:
- Cardiology
- Pharmacology
- Biomedical Engineering
Background:
- Severe left ventricular (LV) failure necessitates effective vasodilator agents.
- Current therapies may have limitations in improving cardiac function and energetics.
Purpose of the Study:
- To evaluate the cardiocirculatory effects of Prostaglandin E1 (PGE1) in patients with severe left ventricular failure.
- To determine PGE1's potential as a vasodilator for treating ischemic congestive heart failure.
Main Methods:
- Investigated the effects of PGE1 infusion in nine patients with coronary artery disease and severe LV failure.
- Monitored systemic blood pressure, LV filling pressure, heart rate, cardiac index, stroke index, and vascular resistance.
Main Results:
- PGE1 infusion decreased mean systemic blood pressure and LV filling pressure.
- PGE1 significantly augmented cardiac index, stroke index, and stroke work index.
- Total systemic vascular resistance decreased, while effective endocardial perfusion pressure was maintained.
Conclusions:
- PGE1 is a potent arteriolar vasodilator with beneficial effects on myocardial energetics and cardiac function.
- PGE1 demonstrates significant therapeutic potential for patients suffering from severe ischemic congestive heart failure.
Abstract:
To provide more effective vasodilator agents for the therapy of severe left ventricular (LV) failure the cardiocirculatory actions of prostaglandin E1 (PGE1) were evaluated in nine coronary patients. PGE1 infusion modestly decreased mean systemic blood pressure (85 to 76 mm Hg, p less than 0.025) and LV filling pressure (19 to 15 mm Hg, p less than 0.01) while heart rate was unchanged (p less than 0.05). Simultaneously, PGE1 augmented cardiac index from 1.9 to 2.5 1/min/m2 (p less than 0.005), raised stroke index from 28 to 35 ml/beat m2 (p less than 0.01) and increased stroke work index from 26 to 30 g-m/m2 (p less than 0.02). Additionally, total systemic vascular resistance decreased from 1862 to 1282 dynes-sec-cm-5 (p less than 0.02) and double product of heart rate and systolic blood pressure diminished from 9492 to 8278 mm Hg (p less than 0.02) while the effective endocardial perfusion pressure was maintained (p less than 0.05). Concomitantly, forearm vascular resistance fell, forearm blood flow was raised, and forearm venous tone remained unchanged. Thus, our results demonstrate that PGE2 is a potent arteriolar vasodilator with markedly beneficial effects of myocardial energetics and on cardiac function in patients with severe ischemic congestive cardiac failure.